Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium-177 microspheres
- Development stage
- Unknown
- Lead developer
- Post Graduate Institute of Medical Education and Research
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Administration
- Intra-arterial, Intratumoral
01
Overview
Lutetium-177 microspheres (177Lu-microspheres) are a radiopharmaceutical formulation consisting of microspheres labeled with the beta- and gamma-emitting radioisotope lutetium-177. Developed primarily by the Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, these microspheres are designed for localized radionuclide therapy, such as selective internal radiation therapy (SIRT) or intra-operative radiopharmaceutical therapy (IORPT). The formulation delivers high-dose localized beta radiation to tumor tissues, inducing DNA double-strand breaks and cell death, while the low-energy gamma emissions allow for real-time SPECT/CT imaging and dosimetry. Lutetium-177 microspheres are being investigated for the treatment of unresectable hepatocellular carcinoma (HCC) and as permanent implants for loco-regional breast cancer therapy.
- Other names
- 177Lu-microsphere177Lu-microsphereslutetium Lu 177 microspheres
Beyond the preview
Go deeper on lutetium-177 microspheres.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium-177 microspheres.